ID: ALA2376437

Max Phase: Preclinical

Molecular Formula: C23H25N5O3

Molecular Weight: 419.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)N[C@@H]1CCc2ccc(Oc3cnc4[nH]cc(C(=O)N[C@H](C)C5CC5)c4n3)cc21

Standard InChI:  InChI=1S/C23H25N5O3/c1-12(14-3-4-14)26-23(30)18-10-24-22-21(18)28-20(11-25-22)31-16-7-5-15-6-8-19(17(15)9-16)27-13(2)29/h5,7,9-12,14,19H,3-4,6,8H2,1-2H3,(H,24,25)(H,26,30)(H,27,29)/t12-,19-/m1/s1

Standard InChI Key:  ZLMYXZMBDPHCEG-CWTRNNRKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 419.49

Molecular Weight (Monoisotopic): 419.1957

AlogP: 3.40

#Rotatable Bonds: 6

Polar Surface Area: 109.00

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.42

CX Basic pKa:

CX LogP: 2.25

CX LogD: 2.24

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.57

Np Likeness Score: -0.68

References

1. Jaime-Figueroa S, De Vicente J, Hermann J, Jahangir A, Jin S, Kuglstatter A, Lynch SM, Menke J, Niu L, Patel V, Shao A, Soth M, Vu MD, Yee C..  (2013)  Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.,  23  (9): [PMID:23541670] [10.1016/j.bmcl.2013.03.015]

Source

Source(1):

• Scientific Literature